TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31253162

Group type: EXPERIMENTAL
Intervention: GLY/eFlow (50 μg GLY delivered by eFlow CS nebulizer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GLY/DPI (63 μg GLY delivered by dry powder inhaler)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 μg GLY
Number of subjects: 30
Study: 28317438

Group type: EXPERIMENTAL
Intervention: iFR-guided revascularization
Number of subjects: 2037

Group type: COMPARATOR
Intervention: FFR-guided revascularization
Number of subjects: 2037
Study: 25564570

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 22299818

Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 778
Study: 21981453

Group type: EXPERIMENTAL
Intervention: Low-intensity blood-flow-restricted resistance exercise (20% 1-RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (20% 1-RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (70% 1-RM)
Number of subjects: 10
Study: 19769651

Group type: EXPERIMENTAL
Intervention: DRP training module
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 74
Study: 16467715

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 16 weeks
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 145
Study: 15131555

Group type: EXPERIMENTAL
Intervention: Biphasic Truncated Exponential (BTE) shocks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Monophasic Damped Sine (MDS) shocks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BTE shocks
Number of subjects: 72
Study: 11516923

Group type: EXPERIMENTAL
Intervention: Vocational Problem‐Solving Skills (VPSS), 10 sessions
Number of subjects: 109

Group type: COMPARATOR
Intervention: Interpersonal Problem‐Solving (IPS), 10 sessions
Number of subjects: 109
Study: 9266494

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8350289

Group type: EXPERIMENTAL
Intervention: Positive coping treatment (short training in conscious use of positive self-statements)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Spontaneous processing condition
Number of subjects: 65
Study: 3726165

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Extent of parametrial infiltration
Number of subjects: 296

Group type: COMPARATOR
Intervention: Involvement of the lower third of the vagina
Number of subjects: 296

Group type: COMPARATOR
Intervention: Presence of bullous oedema
Number of subjects: 296

Group type: COMPARATOR
Intervention: Histological differentiation of the disease
Number of subjects: 296
Study: 30165823

Group type: EXPERIMENTAL
Intervention: Triple therapy combining omeprazole, amoxicillin and one of clarithromycin/ciprofloxacin/metronidazole
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Quadruple therapy combining omeprazole, amoxicillin, ciprofloxacin and doxycycline
Number of subjects: 299

Group type: COMPARATOR
Intervention: Metronidazole based triple therapy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Ciprofloxacin based combination therapies
Number of subjects: 299
Study: 27569438

Group type: EXPERIMENTAL
Intervention: ABC-stroke score with hs-cTnT
Number of subjects: 8356

Group type: EXPERIMENTAL
Intervention: ABC-stroke score with hs-cTnI
Number of subjects: 8356

Group type: COMPARATOR
Intervention: CHA2DS2VASc score
Number of subjects: 8356

Group type: COMPARATOR
Intervention: ATRIA score
Number of subjects: 8356
Study: 24281435

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bolus administration of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ibuprofen (IBU)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bolus administration of ibuprofen (IBU)
Number of subjects: 112
Study: 22325800

Group type: EXPERIMENTAL
Intervention: Computer assisted learning programme for interpreting CTG patterns
Number of subjects: 179
Study: 20973707

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10-30 mg/9 hours
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 162
Study: 18520598

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily for 11 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16850317

Group type: EXPERIMENTAL
Intervention: Stretch contractions at 0, 10, 30, 60, and 100% of maximal voluntary effort with steady-state isometric force controlled at 30% of MVC.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive muscle stretching.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stretch contractions at maximal voluntary effort.
Number of subjects: 11
Study: 11069515

Group type: EXPERIMENTAL
Intervention: Topical 5% ALA lotion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Topical 10% ALA lotion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Topical 20% ALA lotion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Topical ALA lotion (5%, 10%, 20%) vs. Vehicle lotion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vivo fluorescence spectroscopy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 6
Study: 8690823

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine XL
Number of subjects: 14
Study: 1686814

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Idazoxan
Number of subjects: 0
Study: 6303213

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 10
Study: 30251622

Group type: EXPERIMENTAL
Intervention: STEPWISE intervention (structured lifestyle education programme)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 414
Study: 29461408

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.025%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study: 27132697

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 7227
Study: 24490841

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT) performed 2 times per week during the first approximately 15 minutes of each PE class
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional PE (Control group)
Number of subjects: 40
Study: 22970150

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (5 × 10^8 CFUs daily for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20950882

Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Number of subjects: 219

Group type: COMPARATOR
Intervention: High dose-rate brachytherapy (HDRBT) alone
Number of subjects: 219
Study: 17560678

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15905011

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: juice (placebo)
Number of subjects: 12
Study: 12414400

Group type: EXPERIMENTAL
Intervention: Anterior ciliary sclerotomy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (contralateral eye)
Number of subjects: 9
Study: 10614553

Group type: EXPERIMENTAL
Intervention: Gerontology education program (GEP)
Number of subjects: 169
Study: 8579030

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1673284

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 6927281

Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxalactam and cefazolin (10 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of moxalactam and cefazolin (10 mg/kg)
Number of subjects: 19
Study: 31689835

Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device (ACD)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Limited lumbar discectomy alone (Control)
Number of subjects: 554
Study: 27696662

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sham-RIC (Control)
Number of subjects: 225
Study: 25546368

Group type: EXPERIMENTAL
Intervention: Twice‐weekly prophylaxis (20‐30 IU kg(‐1))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3‐times‐weekly prophylaxis (30‐40 IU kg(‐1))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined prophylaxis (twice‐weekly and 3‐times‐weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 80
Study: 24203649

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (RIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithyroid drug therapy (ATD)
Number of subjects: 0
Study: 22719910

Group type: EXPERIMENTAL
Intervention: Low meal Frequency (3 meals per day; LFr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High meal Frequency (14 meals per day; HFr)
Number of subjects: 12
Study: 19375093

Group type: EXPERIMENTAL
Intervention: 4 mg esreboxetine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17302567

Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (4 mg doxazosin)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 117
Study: 15370731

Group type: EXPERIMENTAL
Intervention: Facilitation technique (intensive repetition of movements, more than 100 repetitions a day for each of 5 kinds of movement, applied in two 2-week sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation exercise
Number of subjects: 24
Study: 11775644

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9437205

Group type: EXPERIMENTAL
Intervention: Oral arginine HCl (8.4 g/d) administered to HC subjects for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment in HC subjects
Number of subjects: 0
Study: 8466428

Group type: EXPERIMENTAL
Intervention: Rebox (0 to 300 microA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30773553

Group type: EXPERIMENTAL
Intervention: Digital occlusal splint (experimental group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional soft occlusal splint (control group)
Number of subjects: 24
Study: 29589500

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 2546

Group type: COMPARATOR
Intervention: Standard sutures
Number of subjects: 2546
Study: 27669680

Group type: EXPERIMENTAL
Intervention: Lubiprostone (8 μg b.d.)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 23550786

Group type: EXPERIMENTAL
Intervention: External focus of attention (image of the achievement)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Internal focus of attention (image of the act)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 36
Study: 23433435

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m² weekly for 6 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m² weekly with a loading dose of 400 mg/m² for 6 weeks)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard RT (elective RT up to 54.25 Gy with SIB to 70 Gy in 35 fractions over 6 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Redistributed adaptive RT (elective RT up to 54.25 Gy with SIB between 64-80 Gy in 35 fractions over 6 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Correlation of median (89)Zr-Cetuximab uptake and biological markers with treatment specific outcome
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Swallowing function preservation
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Progression free survival
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 268
Study: 21175446

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18971537

Group type: EXPERIMENTAL
Intervention: Losartan (25-100 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Calcium Channel Blocker (CCB)
Number of subjects: 65
Study: 16649855

Group type: EXPERIMENTAL
Intervention: Attitudes based on behaviorally relevant knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complexity of knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-behavioral relevance knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amount of knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complexity effect
Number of subjects: 0
Study: 14636806

Group type: EXPERIMENTAL
Intervention: Pathways intervention (classroom curriculum, food service, physical activity, and family modules)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Pathways intervention
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1704
Study: 10946911

Group type: EXPERIMENTAL
Intervention: Pegvisomant 30 mg or 80 mg weekly for 6 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pegvisomant 10‐20 mg/d for 12 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8836654

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200, 375 and 1,000 micrograms b.i.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200, 400 and 1,000 micrograms b.i.d.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1477853

Group type: EXPERIMENTAL
Intervention: Magnesium pidolate (15 mmol/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7192153

Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol) 1000 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hydrocodone 10 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen plus hydrocodone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 31439684

Group type: EXPERIMENTAL
Intervention: Early menopause (<45 years)
Number of subjects: 94742

Group type: COMPARATOR
Intervention: Normal menopause (45-55 years)
Number of subjects: 94742

Group type: EXPERIMENTAL
Intervention: Observational analysis of early menopause
Number of subjects: 94742

Group type: COMPARATOR
Intervention: Observational analysis of normal menopause
Number of subjects: 94742
Study: 28133908

Group type: EXPERIMENTAL
Intervention: Multi-time point-based multimarker panel of biomarkers (NT-proBNP, hs-cTnT, sST2, GDF-15, cystatin-C, galectin-3, hs-CRP)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Repeat measurement of NT-proBNP and cystatin-C on day 2
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Further measurements of hs-cTnT, GDF-15, sST2, and hs-CRP on days 14 and 60
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Individual biomarker additions on top of the baseline model
Number of subjects: 1161
Study: 26556478

Group type: EXPERIMENTAL
Intervention: Font size (large vs small) for learners making JOLs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Font size (large vs small) for observers making JOLs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Font size (large vs small) for participants making belief-based recall predictions
Number of subjects: 0
Study: 24312277

Group type: EXPERIMENTAL
Intervention: Higher HIV diversity in the pol region prior to ART initiation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 139
Study: 21273927

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus DBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Globus pallidus internus DBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall DBS cohort
Number of subjects: 0
Study: 18945924

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17675592

Group type: EXPERIMENTAL
Intervention: Uncompressed acoustic stimuli
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Temporally compressed stimuli
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Temporally expanded stimuli
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Frequency compressed and expanded conditions
Number of subjects: 60
Study: 16600222

Group type: EXPERIMENTAL
Intervention: Oral carnitine (2,000 mg L-carnitine and 1,000 mg L-acetyl-carnitine per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12686329

Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: dalteparin
Number of subjects: 141

Group type: COMPARATOR
Intervention: unfractionated heparin (UFH)
Number of subjects: 141
Study: 10599875

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) at doses of 25, 50, and 75 microg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7862477

Group type: EXPERIMENTAL
Intervention: Supplementary carrying intervention
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Increased parental responsiveness intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 2127046

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 24
Study: 7295193

Group type: EXPERIMENTAL
Intervention: Dietary treatment (fat-controlled, low cholesterol diet)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Clofibrate treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (normal blood lipid values)
Number of subjects: 99
Study: 29773947

Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BFF MDI 80/9.6 μg
Number of subjects: 180

Group type: COMPARATOR
Intervention: BD MDI 320 μg
Number of subjects: 180
Study: 27521179

Group type: EXPERIMENTAL
Intervention: 3D printing technology (3DPT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Thin-layer CT scan (control)
Number of subjects: 66
Study: 25707610

Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/5-FU
Number of subjects: 0
Study: 24386491

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the quadriceps, ideally daily sessions of 30 minutes, minimum three times weekly
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care without NMES
Number of subjects: 49
Study: 20577660

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5 microg/h to 20 microg/h
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19047364

Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exenatide 15 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15954961

Group type: EXPERIMENTAL
Intervention: Ephedrine (210 microg kg(‐1)) + Rocuronium (0.04 mg kg(‐1)) with 3-min priming interval
Number of subjects: 31

Group type: COMPARATOR
Intervention: Rocuronium (0.04 mg kg(‐1)) with 3-min sham priming
Number of subjects: 31

Group type: COMPARATOR
Intervention: Rocuronium (0.44 mg kg(‐1)) with 3-min sham priming
Number of subjects: 31

Group type: COMPARATOR
Intervention: Rocuronium (0.04 mg kg(‐1)) with 3-min priming and normal saline
Number of subjects: 31
Study: 12772736

Group type: EXPERIMENTAL
Intervention: 100% nitrogen exposure (anoxia)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal air exposure (control)
Number of subjects: 9
Study: 10485352

Group type: EXPERIMENTAL
Intervention: Split virus vaccine
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit virus vaccine (SU/MF59)
Number of subjects: 194
Study: 7573993

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and General anesthesia
Number of subjects: 50
Study: 1951567

Group type: EXPERIMENTAL
Intervention: Protocol A (n = 32) - Incremental increases of oxytocin of 1 mU/min at 30‐minute intervals
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Protocol B (n = 48) - Incremental increases of oxytocin of 2 mU/min at 15‐minute intervals
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 80
Study: 6109059

Group type: EXPERIMENTAL
Intervention: Hycanthone 0.75 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hycanthone 1.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 31633261

Group type: COMPARATOR
Intervention: Accelerated sham rTMS
Number of subjects: 0
Study: 31847888

Group type: EXPERIMENTAL
Intervention: Mission Papillagou program
Number of subjects: 520